| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |



Departments of Pediatrics and Physiology, University of California San Francisco, San Francisco, California 94143
Abstract
We evaluated the regulation of GH secretion in the unanesthetized dog by systemic administration of drugs which affect noradrenergic and dopaminergic receptors. L-Dihydroxyphenylalanine (L-dopa) produced significant increments in plasma GH, but with associated emesis and significant increases in plasma corticoids and blood pressure (BP). Apomorphine, a dopamine receptor agonist, similarly produced GH elevation only when given in emetic doses, again with increases in corticoids and BP. The dopamine receptorblocking drug, pimozide, did not modify the GH or glucose response to L-dopa, although it abolished emesis and changes in BP and corticoids. Inhibition of peripheral decarboxylation of L-dopa with carbidopa completely blocked the GH and glucose responses to L-dopa. Clonidine, an a receptor agonist, produced significant secretion of GH without affecting BP or the concentration of plasma corticoids.
The failure of pimozide to modify the GH response to L-dopa, and the stimulatory GH response to clonidine suggest that GH release in the dog is regulated predominantly by noradrenergic rather than dopaminergic mechanisms. Further, the response to emetic, but not subemetic, doses of apomorphine indicates that the stress of emesis may act as a stimulus for GH release in the conscious dog. The data from the carbidopa experiments indicate that in the conscious, as opposed to the anesthetized state, the GH response to L-dopa has a peripheral component.
Carbidopa, although significantly attenuating the emesis and behavioral responses seen with L-dopa alone, did not prevent the increase in corticoid concentration which occurred in all of the animals. The inhibition of the corticoid response to L-dopa by pimozide suggests that in the conscious dog, this central stimulatory activity of L-dopa may be mediated by a dopaminergic reoeptor. (Endocrinology 102: 1452, 1978)
Footnotes
* This work was supported in part by grants from the NICHHD, NIAMDD, NIH, USPHS, and the Kroc Foundation. This study was presented at the 59th Annual Meeting of the Endocrine Society, Chicago, June 1977.
Trainee in Pediatric Endocrinology, supported by Samuel McLaughlin Fellowship, University of Toronto, Canada.
Trainee in Pediatric Endocrinology under program sponsored by NIAMDD, NIH, USPHS.
To whom requests for reprints should be addressed.
Received July 28, 1977.
This article has been cited by other articles:
![]() |
A. Ben-Shlomo, I. Miklovsky, S.-G. Ren, W. H. Yong, A. P. Heaney, M. D. Culler, and S. Melmed Leukemia Inhibitory Factor Regulates Prolactin Secretion in Prolactinoma and Lactotroph Cells J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 858 - 863. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. H. Slover, G. J. Klingensmith, R. W. Gotlin, and J. Radcliffe A Comparison of Clonidine and Standard Provocative Agents of Growth Hormone Arch Pediatr Adolesc Med, March 1, 1984; 138(3): 314 - 317. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |